The Advantages and Disadvantages of Medication-Assisted Treatment in Primary Care Offices
- PMID: 31800513
- DOI: 10.1097/JAN.0000000000000305
The Advantages and Disadvantages of Medication-Assisted Treatment in Primary Care Offices
Abstract
Substance use disorder (SUD), more specifically opioid use disorder, is a national epidemic. Although there is an emphasis on treatment and increasing treatment locations, there continues to be a gap between the number of people with SUD and the number of treatment centers. To help narrow this gap, some primary care clinicians started providing medication-assisted treatment (MAT) on an outpatient basis in their offices. This option enables clinicians to provide treatment in their own communities, which increases access to treatment and decreases costs. It also enables the clinician and the person with SUD/opioid use disorder to build a relationship, which many clinicians believe is the foundation of successful treatment. The clinician, whether a doctor, a physician assistant, or an advanced practice nurse, has to obtain a Drug Addiction Treatment Act 2000 waiver to provide MAT beyond naltrexone, which has a required educational program and includes a limitation on the number of clients. Conversely, a possible drawback to this type of treatment is the potential for the disruption of continuity of care with regard to psychotherapy treatment. Federal law mandates that therapy is available and provided to people receiving MAT. The clinician may not be able to provide this service and would need to refer the person with SUD for psychotherapy treatment. It may be clinically significant for a type of follow-up communication to be implemented so that the clinician and the therapy provider can maximize SUD treatment success.
Comment in
-
Addiction Nurses' Roles Across the Lifespan and Settings.J Addict Nurs. 2019 Oct/Dec;30(4):235. doi: 10.1097/JAN.0000000000000303. J Addict Nurs. 2019. PMID: 31800511 No abstract available.
-
Letter to the Editor.J Addict Nurs. 2020 Jul/Sep;31(3):144. doi: 10.1097/JAN.0000000000000343. J Addict Nurs. 2020. PMID: 32868605 No abstract available.
Similar articles
-
The Los Angeles County hub-and-provider network for promoting the sustained use of extended-release naltrexone (XR-NTX) in Los Angeles County (2010-2015).J Subst Abuse Treat. 2018 Feb;85:78-83. doi: 10.1016/j.jsat.2017.02.011. Epub 2017 Mar 11. J Subst Abuse Treat. 2018. PMID: 28291571
-
Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.Addiction. 2019 Mar;114(3):471-482. doi: 10.1111/add.14436. Epub 2018 Oct 15. Addiction. 2019. PMID: 30194876
-
Medication-assisted treatment for opioid use disorder.Nurse Pract. 2019 Mar;44(3):10-12. doi: 10.1097/01.NPR.0000550252.04526.79. Nurse Pract. 2019. PMID: 30585906 No abstract available.
-
Medication-Assisted Treatment of Adolescents With Opioid Use Disorders.Pediatrics. 2016 Sep;138(3):e20161893. doi: 10.1542/peds.2016-1893. Epub 2016 Aug 22. Pediatrics. 2016. PMID: 27550978 Review.
-
Medication-assisted treatment of opioid use disorder: review of the evidence and future directions.Harv Rev Psychiatry. 2015 Mar-Apr;23(2):63-75. doi: 10.1097/HRP.0000000000000075. Harv Rev Psychiatry. 2015. PMID: 25747920 Review.
Cited by
-
Development and implementation of a physician-pharmacist collaborative practice model for provision and management of buprenorphine/naloxone.Ment Health Clin. 2021 Jan 8;11(1):35-39. doi: 10.9740/mhc.2021.01.035. eCollection 2021 Jan. Ment Health Clin. 2021. PMID: 33505825 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous